Premium
Investigating Therapeutic Approach of IBD Using Recombinant Glycoprotein Mucin2
Author(s) -
LI XIAOXIAO,
Wei Bo,
Goodglick Lee,
Wen Tao,
Xia Lijun,
Braun Jonathan
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.570.1
Subject(s) - mucin , recombinant dna , inflammatory bowel disease , glycoprotein , ulcerative colitis , pathogenesis , inflammation , immunology , colitis , medicine , gastrointestinal tract , glycan , immune system , intestinal mucosa , disease , biology , pathology , microbiology and biotechnology , biochemistry , gene
Inflammatory bowel disease (IBD) is characterized by a chronically inflamed mucosa of the gastrointestinal tract, caused by an underlying immune imbalance and alteration of mucosal barrier function. No effective medical cure has been developed for IBD due to our limited understanding of disease pathogenesis. Previous studies have demonstrated that the patients with Ulcerative colitis (UC)‐like mucosal inflammation exhibit a disrupted mucosal barrier. We speculate that the alteration of mucosal barrier integrity is initiated by the destructive interactions between abnormal enteric microbiota and mucous layer. Consistently, analysis of O‐glycan, a major component of colonic mucin in bowel rinse samples from patients with UC has revealed an alteration of mucin structure. This study further explores a novel therapeutic approach for IBD treatment by using exogenous recombinant glycoprotein to block the harmful interactions driven by the colonic bacteria. We established the CHO‐DG44 cell lines producing a recombinant Mucin2, the most abundant secretary glycoprotein in the colon and characterized the O‐glycans on the recombinant Mucin2 protein. Purified O‐glycosylated Mucin2 are being evaluated for the therapeutic effect in the mice model of mucosal inflammation caused by an impaired mucosal barrier. The study would provide a proof of concept to the therapeutic benefit of treating human IBD with recombinant glycoprotein administration.